Apollonio Dorie, Glantz Stanton A
Dorie Apollonio is with the Center for Tobacco Control Research and Education, Department of Clinical Pharmacy, University of California, San Francisco. Stanton A. Glantz is with the Center for Tobacco Control Research and Education, Department of Medicine, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
Am J Public Health. 2017 Oct;107(10):1636-1642. doi: 10.2105/AJPH.2017.303935. Epub 2017 Aug 17.
Nicotine replacement therapy (NRT) is recommended for tobacco cessation on the basis of pharmaceutical industry research showing its effectiveness when combined with counseling. The tobacco industry opposed NRT when it first appeared in the 1980s but by 2016 was marketing its own NRT products. We used internal tobacco industry documents dated 1960 through 2010 to identify the industry's perceptions of NRT. As early as the 1950s, tobacco companies developed nonsmoked nicotine replacements for cigarettes, but they stopped out of concern that marketing such products would trigger Food and Drug Administration regulation of cigarettes. In the 1990s, after pharmaceutical companies began selling prescription NRT, tobacco companies found that many smokers used NRT to supplement smoking rather than to quit. In 2009, once the Food and Drug Administration began regulating tobacco, tobacco companies restarted their plans to capture the nicotine market. Although the tobacco industry initially viewed NRT as a threat, it found that smokers often combined NRT with smoking rather than using it as a replacement and began marketing their own NRT products.
基于制药行业的研究表明尼古丁替代疗法(NRT)与咨询相结合时具有有效性,因此推荐使用该疗法来戒烟。烟草行业在20世纪80年代NRT首次出现时表示反对,但到2016年却在推销自己的NRT产品。我们利用了1960年至2010年的烟草行业内部文件来确定该行业对NRT的看法。早在20世纪50年代,烟草公司就开发了用于香烟的非吸烟用尼古丁替代品,但出于对推销此类产品会引发食品药品监督管理局对香烟进行监管的担忧,他们停止了相关研发。20世纪90年代,制药公司开始销售处方NRT后,烟草公司发现许多吸烟者使用NRT是为了补充吸烟而非戒烟。2009年,一旦食品药品监督管理局开始对烟草进行监管,烟草公司就重启了其抢占尼古丁市场的计划。尽管烟草行业最初将NRT视为一种威胁,但它发现吸烟者经常将NRT与吸烟结合使用而非用其替代吸烟,于是开始推销自己的NRT产品。